Talk Business of Biotech track
Beyond the Race to IND: Balancing Speed, Risk and Future Value
Mon, Nov 9, 2026 · 3:30–3:55 PM CET Business of Biotech Stage, Koelnmesse
About this session
Over the past decade, accelerated development timelines have gone from being a competitive advantage to becoming an industry expectation. Today, reaching the clinic faster can influence everything from fundraising and partnering opportunities to portfolio strategy and company valuation. Yet speed alone is rarely the goal. For biotech leaders, the real challenge is understanding where acceleration creates value, where it can introduce unnecessary risk or unwanted consequences, and how early decisions can shape a program long after IND.
